Cross-Validation of High-Resolution Melting Analysis-Based Genotyping Platform.

Area of Science:

• Clinical molecular diagnostics
• Pharmacogenetics
• Precision medicine

Background:

• Genetic and pharmacogenetic panels are crucial for advancing clinical molecular diagnostics and precision medicine.
• The vitamin K epoxide reductase complex 1 (VKORC1) and CYP2C9 genes are key targets for drug therapy optimization.
• Accurate genotyping platforms are essential for reliable genetic testing.

Purpose of the Study:

• To cross-validate the performance of Canon's multiplex high-resolution DNA melting analysis platform.
• To compare Canon's platform against Applied Biosystems TaqMan-based Quant Studio Real-Time PCR and Pyrosequencing genotyping platforms.
• To assess genotyping accuracy for common VKORC1 and CYP2C9 polymorphisms.

Main Methods:

• Genomic DNA was isolated from 240 blood and saliva samples.
• Single-nucleotide polymorphisms (SNPs) VKORC1-1639 G/A (rs9923231), CYP2C9*2 (430C>T, rs28371674), and CYP2C9*3 (1075A>C, rs1057910) were genotyped.
• Three distinct genotyping platforms were utilized for comparison.

Main Results:

• High concordance rates were observed: 99.2% for VKORC1 and 100% for CYP2C9 SNPs using blood DNA.
• 100% concordance was achieved across all three platforms for the tested SNPs in saliva DNA.
• The Canon DNA analyzer demonstrated excellent agreement with established genotyping methods.

Conclusions:

• The Canon DNA analyzer performs reliably when compared to TaqMan and Pyrosequencing platforms.
• Its capability for multiplex testing and rapid turnaround time makes it suitable for clinical settings.
• This platform can aid in efficient genetic testing, preventing delays in drug therapy optimization.